IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost

Summary

This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10, 50, or 75 μg IM. This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.

Timeline

Start

2016-04

Primary completion

2017-06

Completion

2017-12

Outcome

Outcome not reported

Stopped (Business): “lack of funding”

Drugs

Indications